ReviewTherapeutics and clinical risk management2021
Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization.
Review in Therapeutics and clinical risk management, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 42 citations in OpenAlex.
- Drug-Drug Interactions in Recently Approved Antibacterials: A Mini Review.European journal of drug metabolism and pharmacokinetics · 2026Review
- Are Oritavancin and Dalbavancin More Cost Effective for Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Medical Center?Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025Article
- Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus.Scientific reports · 2025Article
- Use of Dalbavancin in Treatment of Acute Bacterial Skin and Skin Structure Infections: Case Series from a Canadian Perspective.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2025Article
- Protegrin-1 and Analogues AgainstPharmaceuticals (Basel, Switzerland) · 2025Review
- Long-Acting Antibiotics: New Opportunities Beyond Acute Bacterial Skin and Skin Structure Infections (ABSSSIs)!Antibiotics (Basel, Switzerland) · 2025Article
- Bridging the Gap: A Systematic Review with Expert Opinion on the Use of Dalbavancin for In-Label and Off-Label Indications in Pediatric Patients.Antibiotics (Basel, Switzerland) · 2025Review
- Strategies to Stabilize Dalbavancin in Aqueous Solutions; Section-2: The Effects of 2 Hydroxypropyl-β-Cyclodextrin and Acetate Buffer with and Without Divalent Metal Ions.Pharmaceutics · 2024Article
- Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.Infection · 2024Article
- Prescriptive appropriateness of dalbavancin in acute bacterial skin and skin structure infections in adults: an integrated approach between clinical profile, patient- and health system-related factors and focus on environmental impact.Frontiers in antibiotics · 2024Article
- Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection.BMC infectious diseases · 2023Article
- Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study.Antibiotics (Basel, Switzerland) · 2023Article
- Systemic Antibiotic Therapy in Hidradenitis Suppurativa: A Review on Treatment Landscape and Current Issues.Antibiotics (Basel, Switzerland) · 2023Review
- Dalbavancin is thermally stable at clinically relevant temperatures against methicillin-sensitiveJournal of bone and joint infection · 2023Article
- The sources of antimicrobial peptides against Gram-positives and Gramnegatives: our research experience.Le infezioni in medicina · 2023Review
- Our Experience over 20 Years: Antimicrobial Peptides against Gram Positives, Gram Negatives, and Fungi.Pharmaceutics · 2022Review
- Dalbavancin in clinical practice in Spain: a 2 year retrospective study.JAC-antimicrobial resistance · 2022Article
- The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa.Antibiotics (Basel, Switzerland) · 2022Article
- MRSA and Skin Infections in Psoriatic Patients: Therapeutic Options and New Perspectives.Antibiotics (Basel, Switzerland) · 2022Article
- In Vitro Activity of Novel Lipopeptides against Triazole-ResistantJournal of fungi (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDalbavancin is a bactericidal lipoglycopeptide active against gram-positives. Its use has been approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
methodsWe conducted a narrative review of the literature on the safety profile of dalbavancin. The bibliographic research was carried out on the PubMed database on 6 November 2020 by seeking combinations of the following keywords: dalbavancin, adverse effects, safety, drug interactions, and skin infections.
resultsFive double-blind Phase 3 randomized clinical trials, 2 open-label randomized trials, and 4 retrospective studies were identified. No statistically significant differences were found between dalbavancin and comparators in the incidence of adverse events. Retrospective studies confirm the low incidence of adverse events.
conclusionDalbavancin is a therapeutic option that has demonstrated an excellent safety profile, also in relation to the other MRSA therapies available. Its use represents a cost-effective solution for the treatment of those patients with ABSSSI who would need hospitalization. One limitation of this study is that most of the available data are from Phase III clinical trials. Further real-life studies with a larger sample size are therefore needed to better assess the safety profile of the dalbavancin, especially to investigate the true incidence of rare adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.